Honors and Awards
Dare to Try Champion, Pfizer Inc. March 2017
P4 APPE Excellence in Communication Award May 2015
ASHP Clinical Skills Competition Semi-Finalist October 2014
Joseph L. Sewall Memorial Pharmacy Scholarship August 2014
Cardinal Health Full Pharmacy Scholarship May 2014
NCPA National Member of the Year March 2013
Bill Gates Millennium Scholarship Aug. 2007 - Aug. 2012
Rhode Island Foundation Scholarship Aug. 2007 - Aug. 2012
Cindi Sounthonevat, PharmD
Pfizer IncGlobal Medical Affairs | New York, NY | July 2016 - Current
Rutgers Pharmaceutical Industry Fellow, Global Medical Affairs
Fellowship in Global Medical Affairs with deliverables in medical strategy, clinical pharmacology, safety, commercial, medical/legal/regulatory approvals and business development across therapeutic areas
HCP Engagement and Digital Strategy.
Project lead on digital strategy piloting the development and dissemination of KOL digital conference highlights at national and international congresses.
Responsible for agency selection and management, content creation, KOL contracts and engagement.
Delivered digital content to 11 countries, reaching over 60,000 HCPs within 24 hours of their presentation at the European Congress for Neuropsychopharmacology (ECNP).
Managed Medical/Legal/Regulatory approvals.
Partnered with colleagues across disciplines and countries to collect key performance indicators; presented best practices to senior leadership.
Formulated a collaborative agreement and acquired partnership with an international psychiatric organization (ECNP).
Interfaced with international thought leaders and professional organizations (APA & ECNP).
Primary point of medical contact to global commercial team to provide appropriate medical input for promotional pieces, support in-market launch activities and strategic medical input for CNS assets
Health and economic burden of under treated depression among patients with cardiovascular disease (CVD) using a US retrospective claims database".
Performed data analysis, developed study design, selected cohorts and defined endpoints.
A real-world study on time-to-initiation and dose optimization of major depressive disorder treatment in the United States".
Assessed time to therapy initiation and time to reach minimum therapeutic dose (MTD) in patients receiving SSRI or SNRI for Major Depressive Disorder.
The Economic Impact of Hospital Antimicrobial Stewardship Programs".
Reviewed and analyzed the cost/benefit of ASPs in key markets (such as EU and US)
Scientific Medical Communication.
Spearheaded strategic implementation of CNSmedicaleducation.com- a highly utilized global digital library of CNS content across therapeutic areas adapted across regions and digital channels.
Created medical content and implementation guide based on local market characteristics with premade communication plans and email communications for local repurposing.
Managed agency partners to ensure the proper medical review of materials prior to submission to regulatory and legal approval
Conducted a pivotal phase 1 randomized bioequivalence study to support registration of a PDE-5 Inhibitor in China in collaboration with global, cross functional teams: statistics, clinical pharmacology, research and development.
Supported NDA submission and met bi-weekly with study team to ensure high quality of data.
Key player in the development of the Statistical Analysis Plan (SAP), Safety Review Plan (SRP) and Clinical Study Report (CSR)
Provided value proposition for a phase III, characterized oral desensitization immunotherapy agent (CODIT); cross functional engagement with EU payers, commercial, business development and medical.
Mapped unmet medical need, opportunity cost, competitive positioning (existing and future), generics, pricing, access, competitive landscape and pipeline considerations.
Performed in-depth review of clinical/regulatory/safety data and market research through Q&A with EU Senior Management.
Key discussion points included:.
Launch plan, including priority markets and information on key customer targets.
Market access plan and information on expected pricing, reimbursement landscape.
Perspectives on product profile relative to competitors such as ViaSkin
Safety: Decision Analysis Tool for Executive Benefit Risk Committee.
Developed and launched a portfolio of educational materials on Multi-Criteria Decision Analysis (MCDA) for the CMO's corporate-wide initiative based on a survey of cross-functional colleagues concerning tofacitinib.
Piloted benefit risk conferencing, produced animated video as a case study featured on internal micro-website and created an in-depth report with reference documents
Developed medical and digital strategies for unbranded programs with regional and country leads.
Led workgroups with the Pfizer Pharmacist Association and Medical Strategy Committees to explore organic growth utilizing "Dare to Try" framework, a selective program aimed at supporting an innovative mindset among Pfizer employees.
Supported interactions with thought leaders and professional organizations including scientific collaborations, speaker training, advisory boards, and regional/national/international conferences
Health and economic burden of under treated depression among patients with cardiovascular disease (CVD) using a US retrospective claims database.
Roger McIntyre, MD, Elizabeth Pappadopulos, PhD, Ahmed Shelbaya, MD.
Cindi Sounthonevat, PharmD
A real-world study on time-to-initiation and dose optimization of major depressive disorder treatment in the United States.
Elizabeth Pappadopulos, PhD, Rita Prieto, MD, Matthieu Boucher, PhD, Ahmed Shelbaya, MD.
Cindi Sounthonevat, PharmD
Celecoxib for the treatment of ankylosing spondylitis.
Journal of Rheumatology and Arthritic Disease.
Cindi Sounthonevat, PharmD, Chris Walker, PhD, Jian Zhu MD.
MTM Considerations in Osteoporosis Care: Current Issues for Prevention and Treatment.